Abstract:Abstract Introduction PAC-C is a randomized, multicenter, phase III study comparing the efficacy and safety of PX-X vs the standard XP regimen as first-line therapy for advanced gastric cancer (AGC). Here we report the findings from a protocol-specified preliminary safety analysis. Methods Patients with previously untreated AGC, evaluable lesion(s) by RECIST 1.0, and KPS≥70 are eligible. All eligible patients are randomized to receive either PX-X or XP. Patients in the PX-X arm receive paclitaxel (80 mg/m2 3-hour infusion on days 1&8) and capecitabine (1000 mg/m2 twice daily on days 1–14) every 3 weeks for a maximum of 4 cycles; subsequently, patients with no disease progression receive maintenance capecitabine monotherapy (same dose/schedule) until progression or intolerable toxicity. Patients in the XP arm receive cisplatin (80 mg/m2 2-hour infusion on day 1) and capecitabine (same dose/schedule as in PX-X arm) for a maximum of 6 cycles. Adverse events (AEs) are evaluated according to CTC-AE (version 3.0). Study drug exposure, AEs and serious AEs (SAEs) were evaluated. The study is registered with ClinicalTrials.gov ID of NCT01015339. Results The study started in November 2009 and is anticipated to finish recruitment by the end of May 2012. Up to 30 June 2011, 160 patients were recruited (81 patients in the PX-X arm and 79 patients in the XP arm). The safety analysis population includes 147 patients (79 in the PX-X arm and 68 in the XP arm). Baseline patient and disease characteristics (median age, gender ratio, and performance status) were similar in the treatment arms. The median number of treatment cycles was 4.0 in each arm (range 1–22 cycles in the PX-X arm and 1–8 cycles in the XP arm). Dose adjustments of platinum or paclitaxel were lower in the PX-X arm (11.4% for paclitaxel) than the XP arm (30.9% for cisplatin); dose adjustments of capecitabine were also lower in the PX-X arm (6.3% vs 22.1% in the XP arm). AEs resulting in dose adjustment or administration delay were lower in the PX-X arm (10.1% vs 19.1%). Gastrointestinal AEs (all grades) were reported in 20.3% of PX-X and 32.4% of XP-treated patients. Grade 3/4 AEs in the PX-X vs XP arms were as follows: gastrointestinal (2.5% vs 5.9%); leukocytopenia (13.9% vs 13.2%); anemia (0% vs 7.4%). SAEs (6.3% vs 4.4%) and treatment-related deaths (1.2% vs 0%) were similar in the two treatment arms. Conclusion This preliminary analysis in 160 patients raises no safety concerns. The current findings suggest that treatment with PX-X is associated with fewer dose adjustments or treatment delays and a lower rate of gastrointestinal AEs than standard treatment with XP. The study is currently nearing completion of accrual.

Capecitabine (X) Combined with Fractionated Cisplatin (C) As First-Line Therapy in Chinese Patients (pts) with Advanced Gastric Carcinoma (AGC)

[Capecitabine Combined with Cisplatin As First-Line Therapy in Chinese Patients with Advanced Gastric Carcinoma-a Phase II Clinical Study].

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Trastuzumab Plus Docetaxel And Capecitabine As A First-Line Treatment For Her2-Positive Advanced Gastric Or Gastroesophageal Junction Cancer: A Phase Ii, Multicenter, Open-Label, Single-Arm Study

Combination Chemotherapy with Paclitaxel, Cisplatin and Fluorouracil for Patients with Advanced and Metastatic Gastric or Esophagogastric Junction Adenocarcinoma: a Multicenter Prospective Study.

Combination of Paclitaxel, Cisplatin, and Fluorouracil in Patients with Advanced and Metastatic Gastric Cancer As First- or Second-Line Therapy: A Multicenter Prospective Study.

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study

Phase II Trial of XELOX As First-Line Treatment for Patients with Advanced Gastric Cancer

Anti-PD-1 Antibody HX008 Combined with Oxaliplatin Plus Capecitabine for Advanced Gastric or Esophagogastric Junction Cancer: a Multicenter, Single-Arm, Open-Label, Phase Ib Trial

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

S-1-Based Chemotherapy Versus Capecitabine-Based Chemotherapy As First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Efficacy and Safety of Epirubicin,Oxaliplatin and Capecitabine as the First-Line Treatment for Patients with Metastatic Gastric Cancer

P-0042 Preliminary Safety Analysis From PAC-C Study of Capecitabine+Paclitaxel→Capecitabine Maintenance (PX-X) vs Capecitabine+Cisplatin (XP) As First-Line Chemotherapy for Recurrent/Metastatic Gastric Cancer